Is PTC Therapeutics on the Road to Recovery?

By Chris Lange Updated Jan 13, 10:42AM EST · Published Apr 15, 12:25PM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Is PTC Therapeutics on the Road to Recovery? — © Thinkstock

PTC Therapeutics Inc. (NASDAQ: PTCT) saw its shares jump late Friday morning on positive news on its nonsense mutation Duchenne muscular dystrophy (nmDMD) treatment. The company announced that the National Institute for Health and Care Excellence (NICE) has recommended Translarna (ataluren) for ambulatory patients aged five years and older with nmDMD in connection with a Managed Access Agreement with NHS England.

It is worth noting that this provision of patient access is subject to the finalization of the NICE draft guidance, which the agency expects in May of 2016. This could be the first step in PTC’s recovery, as the stock has been crushed over the past year.

This company cratered in February after it announced that it received a Refuse to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Translarna. The FDA said in the letter that the application was not sufficiently complete to permit a substantive review. PTC first learned of the Refuse to File decision via this letter and is reviewing its content to determine the appropriate next steps.
[recirclink id=325409]
Paul Lenihan, chief executive of Action Duchenne, commented on the NICE recommendation:

This is an important day for the Duchenne community, which has been working hard to make this ground-breaking drug available to boys with nonsense mutation Duchenne muscular dystrophy. We are delighted by this positive recommendation and NICE’s recognition that Translarna is an important new medicine for patients. This decision is a hugely encouraging sign that both NICE and NHS England have listened to the patient community, bringing hope to each and every parent and patient fighting DMD.

For some background: Translarna is an oral, first-in-class, protein restoration therapy for the treatment of nmDMD. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy.

Shares of PTC were trading up 42.5% at $8.88 on Friday in the noon hour, with a consensus analyst price target of $27.40 and a 52-week trading range of $5.27 to $74.40.

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.